You are here: Industry Insights > MHRA

News List

MHRA sets out Brexit implementation period plan pharmafile
August 08, 2018
The UK Medicines and Healthcare products Regulatory Agency (MHRA) have released an update which sets out what pharmaceutical and healthcare companies should expect from the Brexit implementation period that will run from March 2019 to December 2020.
MHRA clarifies post-Brexit clinical trials rules pharmatimes
August 07, 2018
The MHRA has clarified how the UK’s clinical trials rules will function in partnership with the EU after Britain leaves the Union in March next year.
Alnylam Announces United Kingdom’s MHRA Grants Early Access to Patisiran americanpharmaceuticalreview
August 06, 2018
Alnylam announced the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted patisiran, an investigational RNAi therapeutic in development for the treatment of hATTR amyloidosis, a positive scientific opinion through the Early Access
MHRA bans valproate without pregnancy prevention programme pharmatimes
April 25, 2018
The Medicines and Healthcare products Regulatory Agency (MHRA) has changed the licence for valproate medicines
Newly adopted flu vaccine could save 1,700 lives pharmafile
September 13, 2017
The Fluad flu vaccine, produced by Seqirus, was approved by the MHRA for use beginning in 2018 and further data has been released to back up this decision, showing that a potential 1,700 lives could be saved through its use.
MHRA approves Dovonex Psoriasis Ointment switching to OTC pharmatimes
August 21, 2017
MHRA has approved the switch of Dovonex Psoriasis Ointment from a prescription-only drug to OTC.
Glenmark receives MHRA, UK approval for Maloff Protect expressbpd
July 05, 2017
Maloff Protect is the first OTC approval granted by MHRA, which will be used for the prevention of malaria in adults
MHRA grants positive EAMS scientific opinion for Santhera’s DMD treatment Raxone pharmaceutical-technology
June 27, 2017
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted Swiss company Santhera Pharmaceuticals’ a positive scientific opinion for its Raxone (idebenone) through the Early Access to Medicines Scheme (EAMS).

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page